PMID-sentid Pub_year Sent_text compound_name comp_offset prot_official_name organism prot_offset 18203048-9 2008 RESULTS: The beneficial effect of augmented amisulpride at a daily dose of 600 mg was observed in the mean scores of secondary outcome measures, as assessed by GAF, CGI and MADRS. Amisulpride 44-55 fibroblast growth factor 9 Homo sapiens 160-163 18848860-2 2008 All first generation antipsychotics and the second generation antipsychotics amisulpride and risperidone have been shown to cause marked elevation in serum prolactin levels, whereas most other second generation antipsychotics and aripiprazole appear to have little or no effect on serum prolactin levels. Amisulpride 77-88 prolactin Homo sapiens 156-165 18848860-2 2008 All first generation antipsychotics and the second generation antipsychotics amisulpride and risperidone have been shown to cause marked elevation in serum prolactin levels, whereas most other second generation antipsychotics and aripiprazole appear to have little or no effect on serum prolactin levels. Amisulpride 77-88 prolactin Homo sapiens 287-296 18777019-6 2008 RESULTS AND DISCUSSION: Olanzapine (5 mg/kg), sulpiride (5, or 10 mg/kg), and amisulpride (10 mg/kg) treatments significantly increased the level of Golf protein, but there was no increase with administration of higher doses of these three antipsychotics. Amisulpride 78-89 G protein subunit alpha L Rattus norvegicus 149-153 18710798-6 2008 Amisulpride also displayed functional limbic selectivity in Fos expression like the other atypicals. Amisulpride 0-11 Fos proto-oncogene, AP-1 transcription factor subunit Homo sapiens 60-63 18477617-8 2008 Of those atypicals that are associated with prolactin elevation, the main causative factor appears to be a higher peripheral-to-central dopamine receptor potency of either the parent drug or its active metabolite (e.g. risperidone, 9-hydroxy-risperidone and amisulpride). Amisulpride 258-269 prolactin Homo sapiens 44-53 16874502-4 2007 Hyperprolactinaemia is mainly induced by treatment with risperidone and amisulpride, and there is evidence for more pronounced prolactin levels in females. Amisulpride 72-83 prolactin Homo sapiens 5-14 18063941-12 2007 CONCLUSION: Amisulpride and risperidone had marked and early prolactin elevating effects, requiring, therefore, more frequent monitoring of prolactinaemia and associated undesirable effects and risks than olanzapine, quetiapine and zotepine. Amisulpride 12-23 prolactin Homo sapiens 61-70 17675915-12 2007 Amisulpride, aripiprazole and ziprasidone seem to carry the lowest risk for weight gain, diabetes and effects on insulin resistance. Amisulpride 0-11 insulin Homo sapiens 113-120 17050656-3 2007 We conducted a prospective, open study comparing body weight, parameters of insulin resistance in schizophrenia patients treated with either clozapine (n = 10) or amisuLpride ( n = 12). Amisulpride 163-174 insulin Homo sapiens 76-83 16938372-1 2007 BACKGROUND: Although amisulpride is considered to be a prolactin-raising atypical antipsychotic drug, a limited number of studies have documented the extent of its prolactin-elevating properties. Amisulpride 21-32 prolactin Homo sapiens 55-64 16938372-2 2007 In the present study the effect of amisulpride on plasma levels of prolactin and the reversibility of this untoward side effect were investigated. Amisulpride 35-46 prolactin Homo sapiens 67-76 16938372-7 2007 Following amisulpride discontinuation prolactin levels were significantly (p<000) reduced (mean+/-S.D. Amisulpride 10-21 prolactin Homo sapiens 38-47 16938372-10 2007 CONCLUSION: Amisulpride has a pronounced prolactin-elevating effect which appears to be independent of dosage and duration of administration. Amisulpride 12-23 prolactin Homo sapiens 41-50 17356308-1 2006 The aim of this study was to evaluate the effectiveness and tolerability of both amisulpride and risperidone for treating the behavioral and psychological symptoms of dementia in patients with dementia of the Alzheimer type (DAT). Amisulpride 81-92 solute carrier family 6 member 3 Homo sapiens 225-228 17285098-1 2007 Amisulpride and risperidone are potent dopamine D2 receptor blocking atypical antipsychotics that can cause hyperprolactinemia. Amisulpride 0-11 dopamine receptor D2 Homo sapiens 39-59 16288681-6 2006 In terms of dose, sultopride has about 50 times greater potency than sulpiride based on dopamine D2 receptor occupancy. Amisulpride 18-28 dopamine receptor D2 Homo sapiens 88-108 16252067-0 2006 Cyclosporine A (CsA) affects the pharmacodynamics and pharmacokinetics of the atypical antipsychotic amisulpride probably via inhibition of P-glycoprotein (P-gp). Amisulpride 101-112 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 140-154 16252067-0 2006 Cyclosporine A (CsA) affects the pharmacodynamics and pharmacokinetics of the atypical antipsychotic amisulpride probably via inhibition of P-glycoprotein (P-gp). Amisulpride 101-112 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 156-160 16252067-1 2006 The importance of P-glycoprotein (P-gp) in the pharmacokinetics of amisulpride and the effects of a P-gp inhibitor cyclosporine A (CsA) was investigated both, in vitro and in vivo. Amisulpride 67-78 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 18-32 16252067-1 2006 The importance of P-glycoprotein (P-gp) in the pharmacokinetics of amisulpride and the effects of a P-gp inhibitor cyclosporine A (CsA) was investigated both, in vitro and in vivo. Amisulpride 67-78 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 34-38 16252067-2 2006 In vitro and in vivo results indicated amisulpride as a substrate of P-gp. Amisulpride 39-50 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 69-73 16252067-7 2006 These results pointed to a pharmacokinetic drug interaction between CsA and amisulpride most likely caused by inhibition of P-gp. Amisulpride 76-87 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 124-128 17356308-2 2006 Twenty-eight patients with DAT were randomly assigned to treatment with either amisulpride or risperidone for 8 weeks. Amisulpride 79-90 solute carrier family 6 member 3 Homo sapiens 27-30 17356308-7 2006 This study showed that either amisulpride or risperidone would be effective and tolerable for treating patients with DAT. Amisulpride 30-41 solute carrier family 6 member 3 Homo sapiens 117-120 12144950-3 2002 At doses twice the ED(50), (S-)-amisulpride produced a maximal increase in prolactin level similar to that of the racemic form (403 +/- 21% and 425 +/- 15%, respectively), but higher than that of (R+)-amisulpride (198 +/- 8%). Amisulpride 27-43 prolactin Rattus norvegicus 75-84 15225684-7 2004 This report shows that the short-term use of amisulpride treatment was linked to an elevation in the PRL level with a possible induction of a pituitary adenoma. Amisulpride 45-56 prolactin Homo sapiens 101-104 13130349-0 2003 [Prolactin Levels and Symptoms of Hyperprolactinemia in Patients Treated with Amisulpride, Risperidone, Olanzapine and Quetiapine] Elevations in prolactin plasma concentration occur with antipsychotics due to their dopamine D2 receptor antagonism. Amisulpride 78-89 prolactin Homo sapiens 1-10 13130349-0 2003 [Prolactin Levels and Symptoms of Hyperprolactinemia in Patients Treated with Amisulpride, Risperidone, Olanzapine and Quetiapine] Elevations in prolactin plasma concentration occur with antipsychotics due to their dopamine D2 receptor antagonism. Amisulpride 78-89 prolactin Homo sapiens 39-48 13130349-4 2003 Our findings confirm that amisulpride frequently leads to a remarkable elevation of prolactin plasma concentration, same - in minor degree - for risperidone. Amisulpride 26-37 prolactin Homo sapiens 84-93 14509051-5 2003 Our findings confirm that amisulpride frequently leads to a remarkable elevation of prolactin plasma concentration, same--in minor degree--for risperidone. Amisulpride 26-37 prolactin Homo sapiens 84-93 12165366-1 2002 The aim of the study was to examine the action of low-dose amisulpride (100 mg/d), an atypical antipsychotic from the benzamide class with a high affinity for the D2 and D3 dopamine receptors, given for 4 weeks in 19 schizophrenic patients with the deficit syndrome, in terms of clinical response, modifications in their cognitive performance and changes in brain perfusion values. Amisulpride 59-70 dopamine receptor D2 Homo sapiens 163-204 23573604-5 2002 The preclinical profile of amisulpride shows specificity for D2/D3 dopamine receptors and selective activity in the limbic system. Amisulpride 27-38 dopamine receptor D2 Homo sapiens 61-85 15665803-3 2004 METHODOLOGY: Plasma prolactin levels were measured in 5 males and 5 females with depressive symptoms who were treated with 50 mg of amisulpride per day as an augmentation to antidepressants (n=5), benzodiazepine anxiolytics (n=8) or in monotherapy (n=1). Amisulpride 132-143 prolactin Homo sapiens 20-29 14997280-2 2004 It has not been clarified why some atypical antipsychotic drugs, such as amisulpride, induce prolactin plasma concentration (PRL) elevation, but little EPS. Amisulpride 73-84 prolactin Homo sapiens 125-128 14997280-4 2004 OBJECTIVE: We have evaluated the relationship between PRL and central (striatum, temporal cortex and thalamus) D2/D3 receptor occupancy in amisulpride treated schizophrenic patients. Amisulpride 139-150 prolactin Homo sapiens 54-57 14997280-12 2004 Higher D2/D3 receptor occupancy at the pituitary gland than at central regions is a possible explanation for amisulpride PRL elevation with low EPS. Amisulpride 109-120 prolactin Homo sapiens 121-124 14575800-8 2003 Based on previous studies with risperidone, clozapine and olanzapine we tend to attribute this global interaction with the opioid system to amisulpride"s action at the dopamine D2 receptor sites. Amisulpride 140-151 dopamine receptor D2 Mus musculus 168-188 9894580-7 1999 The prolactin response to TRH was significantly blunted by amisulpride only in male subjects. Amisulpride 59-70 thyrotropin releasing hormone Homo sapiens 26-29 12232542-18 2002 The pattern of prescribing practices that emerges from our four surveys suggests that these new AAP are significantly more and more often associated with a stabilizer mood drug (p<0.009) (particularly the olanzapine) or/and an anxiolytic drug (p<0.05) (like the amisulpride in particular). Amisulpride 268-279 serpin family F member 2 Homo sapiens 96-99 12232542-21 2002 Then, concerning the psychotic patients, the AAP were significantly more often associated with other neuroleptic agents (p<0.03), the amisulpride in particular, with anticholinergic drugs (p<0.00005), but significantly less with mood stabilizer drugs (p<0.00003) principally the amisulpride and the risperidone, with antidepressant drugs (p<0.02) particularly the risperidone. Amisulpride 137-148 serpin family F member 2 Homo sapiens 45-48 12232542-21 2002 Then, concerning the psychotic patients, the AAP were significantly more often associated with other neuroleptic agents (p<0.03), the amisulpride in particular, with anticholinergic drugs (p<0.00005), but significantly less with mood stabilizer drugs (p<0.00003) principally the amisulpride and the risperidone, with antidepressant drugs (p<0.02) particularly the risperidone. Amisulpride 288-299 serpin family F member 2 Homo sapiens 45-48 12693427-3 2002 In all studies a significant improvement was observed on the Scale for the Assessment of Negative Symptoms (SANS) in the amisulpride groups (50-300 mg daily) as compared to placebo. Amisulpride 121-132 USH1 protein network component sans Homo sapiens 108-112 11270918-0 2001 In vivo extrastriatal and striatal D2 dopamine receptor blockade by amisulpride in schizophrenia. Amisulpride 68-79 dopamine receptor D2 Homo sapiens 35-55 11873706-7 2002 The newer, atypical antipsychotics such as quetiapine, remoxipride, clozapine, olanzapine, sertindole, ziprasidone, and amisulpride all bind more loosely than dopamine to the dopamine D2 receptor and have dissociation constants higher than that for dopamine. Amisulpride 120-131 dopamine receptor D2 Homo sapiens 175-195 12207145-0 2002 Long-term effects of the substituted benzamide derivative amisulpride on baseline and stimulated prolactin levels. Amisulpride 58-69 prolactin Homo sapiens 97-106 12207145-10 2002 The prolactin secretion was initially increased over tenfold by amisulpride. Amisulpride 64-75 prolactin Homo sapiens 4-13 12207145-14 2002 Notably, in the amisulpride group, 3 months after cessation of treatment at month 12, the elevated levels of prolactin returned to baseline at month 15. Amisulpride 16-27 prolactin Homo sapiens 109-118 12207145-15 2002 In summary, amisulpride demonstrated more pronounced effects than flupenthixol on the prolactin levels. Amisulpride 12-23 prolactin Homo sapiens 86-95 12207145-16 2002 However, the findings indicate also that treatment with amisulpride at clinically effective doses can be achieved at significantly lower prolactin levels during the long-term maintenance phase than during the prior acute phase. Amisulpride 56-67 prolactin Homo sapiens 137-146 10594669-3 1999 In contrast, the selective D2 vs. 5-HT2A antagonists, eticlopride, raclopride and amisulpride, preferentially inhibited ALOC vs. PLOC. Amisulpride 82-93 5-hydroxytryptamine receptor 2A Rattus norvegicus 34-40 10200742-2 1999 OBJECTIVE: The goal of this placebo-controlled study was to evaluate the efficacy and safety of low doses of amisulpride, an atypical antipsychotic of the benzamide class with high affinity for D2 and D3 dopamine receptors, in the treatment of schizophrenic patients with predominantly primary negative symptoms. Amisulpride 109-120 dopamine receptor D2 Homo sapiens 194-222 9894580-8 1999 While basal TSH secretion was significantly increased by both compounds, TRH-stimulated TSH secretion was elevated only in patients treated with amisulpride. Amisulpride 145-156 thyrotropin releasing hormone Homo sapiens 73-76 9165379-2 1997 Amisulpride, a selective antagonist of D2 and D3 dopamine receptors, acts preferentially on presynaptic receptors increasing dopaminergic transmission at low doses. Amisulpride 0-11 dopamine receptor D2 Homo sapiens 39-67 9892856-1 1999 Amisulpride, a selective antagonist for D2 and D3 dopamine receptors, acts preferentially on presynaptic receptors increasing dopaminergic transmission at low doses. Amisulpride 0-11 dopamine receptor D2 Homo sapiens 40-68 9218164-6 1997 Mean total scores for the Scale for the Assessment of Negative Symptoms (SANS) at baseline in the different treatment groups varied from 98 to 74, and improved significantly in the amisulpride groups (mean change from 24 to 40 points) compared with the placebo groups. Amisulpride 181-192 USH1 protein network component sans Homo sapiens 73-77 9545996-0 1998 Binding of antipsychotic drugs to cortical 5-HT2A receptors: a PET study of chlorpromazine, clozapine, and amisulpride in schizophrenic patients. Amisulpride 107-118 5-hydroxytryptamine receptor 2A Homo sapiens 43-49 7894879-6 1995 RESULTS: Both amisulpride doses were significantly more effective than placebo on the primary evaluation criterion (SANS total score, MANOVA P < 0.02). Amisulpride 14-25 USH1 protein network component sans Homo sapiens 116-120 8996184-0 1997 Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity. Amisulpride 33-44 dopamine receptor D3 Rattus norvegicus 88-108 8996184-5 1997 of amisulpride were needed to block grooming behavior observed after a short period in water, a D1 receptor-mediated behavior. Amisulpride 3-14 dopamine receptor D1 Mus musculus 96-107 8996185-8 1997 The present data characterize amisulpride as a specific dopamine receptor antagonist with high and similar affinity for the dopamine D2 and D3 receptor. Amisulpride 30-41 dopamine receptor D3 Rattus norvegicus 124-151 7802104-1 1995 OBJECTIVE: The authors assessed the effects on primary negative symptoms of low doses of amisulpride, a substituted benzamide neuroleptic with high affinity for D2 and D3 dopamine receptors. Amisulpride 89-100 dopamine receptor D2 Homo sapiens 161-189 8935811-0 1996 In vivo characteristics of dopamine D2 receptor occupancy by amisulpride in schizophrenia. Amisulpride 61-72 dopamine receptor D2 Homo sapiens 27-47 34614447-1 2022 BACKGROUND: Non-racemic amisulpride (SEP-4199) is an 85:15 ratio of aramisulpride:esamisulpride with a 5-HT7 and D2 receptor binding profile optimized for the treatment of bipolar depression. Amisulpride 24-35 5-hydroxytryptamine receptor 7 Homo sapiens 103-108 35615528-6 2022 At the age 57 years, she developed manic symptoms while on treatment with amisulpride for six weeks. Amisulpride 74-85 Src homology 2 domain containing E Homo sapiens 21-24 34197589-4 2021 In an independent sample, we determined the modulatory role of dopamine in reinforcement learning following a single dose of the dopamine D2/3 receptor antagonist amisulpride (400 mg) and the agonist pramipexole (0.5 mg) in a randomised, double-blind, placebo-controlled, crossover design. Amisulpride 163-174 dopamine receptor D2 Homo sapiens 129-151 34481200-9 2021 Newer antipsychotics (risperidone, amisulpride and paliperidone) and older antipsychotics (chlorpromazine, haloperidol and sulpride) increase prolactin levels with large effect sizes. Amisulpride 35-46 prolactin Homo sapiens 142-151 34658963-9 2021 In addition, when risperidone, amisulpride, and olanzapine were the primary AP medications, adjunctive paeoniae/glycyrrhiza = 1:1, aripiprazole <5 mg/day, and aripiprazole >10 mg/day were the most effective treatments in reducing the prolactin levels, respectively. Amisulpride 31-42 prolactin Homo sapiens 234-243 34408155-9 2021 Prolactin levels were higher in women than in men, especially for amisulpride (p < 0.001). Amisulpride 66-77 prolactin Homo sapiens 0-9 33928659-10 2021 The linear range of amisulpride was 48.15 ng ml-1 -2407.59 ng ml-1 , while the extraction recovery was in the range from 98.7% to 101.3%. Amisulpride 20-31 interleukin 17F Homo sapiens 45-49 4030988-3 1985 Internal standards were a new substituted benzamide (N-[(ethyl-1-pyrrolidinyl-2)methyl] methoxy-2-ethylsulphonyl-5-benzamide, DAN) for the sulpiride assay and sulpiride for the sultopride assay. Amisulpride 177-187 NBL1, DAN family BMP antagonist Homo sapiens 126-129 6424592-0 1984 Effect of sultopride on prolactin secretion in rats. Amisulpride 10-20 prolactin Rattus norvegicus 24-33 6424592-1 1984 Oral administration of sultopride caused a significant and dose-related increase in serum prolactin levels in the rat. Amisulpride 23-33 prolactin Rattus norvegicus 90-99 6424592-2 1984 Sultopride was 4-6 times as potent as sulpiride in stimulating prolactin secretion. Amisulpride 0-10 prolactin Rattus norvegicus 63-72 6424592-4 1984 CB-154, a dopamine agonist, inhibited the sultopride-induced prolactin release. Amisulpride 42-52 prolactin Rattus norvegicus 61-70 6424592-5 1984 Stereoselective activity of sultopride-isomers was observed in increasing rat prolactin secretion. Amisulpride 28-38 prolactin Rattus norvegicus 78-87 6424592-8 1984 Prolactin response 1 hr after sultopride administration was observed throughout the experiments. Amisulpride 30-40 prolactin Rattus norvegicus 0-9 6424592-9 1984 Sultopride neutralized the dopamine-mediated inhibition of prolactin secretion from the anterior pituitary in vitro. Amisulpride 0-10 prolactin Rattus norvegicus 59-68 6424592-10 1984 These results suggest that sultopride, like sulpiride, stimulates prolactin secretion by blocking the dopamine receptor in the pituitary. Amisulpride 27-37 prolactin Rattus norvegicus 66-75 35131596-11 2022 CONCLUSION: Treatment with amisulpride, aripiprazole and olanzapine showed different effects on CRP levels in patients with schizophrenia spectrum disorders, modified by previous antipsychotics exposure status. Amisulpride 27-38 C-reactive protein Homo sapiens 96-99 35242209-0 2022 Changes of Mental State and Serum Prolactin Levels in Patients with Schizophrenia and Depression after Receiving the Combination Therapy of Amisulpride and Chloroprothixol Tablets. Amisulpride 140-151 prolactin Homo sapiens 34-43 35242209-1 2022 Objective: To investigate the changes in mental state and serum prolactin levels in patients with schizophrenia and depression after receiving the combination therapy of amisulpride and chloroprothixol tablets. Amisulpride 170-181 prolactin Homo sapiens 64-73 7337503-6 1981 Serum sultopride levels reached peak 1 hr after the administration and declined with an apparent half life of 3.5 hr, while serum sulpiride levels increased gradually and the high serum level at 2 hr remained for up to 6 hr. Amisulpride 6-16 pseudopodium-enriched atypical kinase 1 Oryctolagus cuniculus 32-38 33928659-10 2021 The linear range of amisulpride was 48.15 ng ml-1 -2407.59 ng ml-1 , while the extraction recovery was in the range from 98.7% to 101.3%. Amisulpride 20-31 interleukin 17F Homo sapiens 62-66 31842924-13 2019 CONCLUSIONS: Together our research indicates that the increased sensitivity of individuals with Alzheimer"s to amisulpride is related to previously unreported changes in function and expression of SLC transporters at the BBB (in particular PMAT and MATE1). Amisulpride 111-122 solute carrier family 29 member 4 Homo sapiens 240-244 32800810-0 2020 Amisulpride alleviates chronic mild stress-induced cognitive deficits: Role of prefrontal cortex microglia and Wnt/beta-catenin pathway. Amisulpride 0-11 catenin beta 1 Rattus norvegicus 115-127 32800810-4 2020 Hitherto, the direct effects of amisulpride on Wnt/beta-catenin signaling and microglial activity have not been thoroughly studied. Amisulpride 32-43 catenin beta 1 Rattus norvegicus 51-63 32800810-5 2020 This study aimed at investigating the effects of chronic amisulpride treatment on Wnt/beta-catenin signaling and pro-inflammatory microglial activation and its role in alleviation of depressive-like behavior and cognitive deficits elicited by unpredictable chronic mild stress (UCMS). Amisulpride 57-68 catenin beta 1 Rattus norvegicus 86-98 32800810-9 2020 Amisulpride improved UCMS-induced behavioral/cognitive deficits, ameliorated Wnt/beta-catenin signaling dysregulation and pro-inflammatory microglial activation. Amisulpride 0-11 catenin beta 1 Rattus norvegicus 81-93 32800810-10 2020 This work highlights the antidepressant and pro-cognitive effects of amisulpride in UCMS-exposed rats that could be mediated by modulation of Wnt/beta-catenin pathway activity and amelioration of pro-inflammatory microglial activation in the prefrontal cortex. Amisulpride 69-80 catenin beta 1 Rattus norvegicus 146-158 32293194-7 2020 A scenario analysis with updated olanzapine unit cost suggested an ICER of 7,857 USD/QALY.Conclusions: Amisulpride is likely to be a cost-effective option with increased effectiveness compared with olanzapine in the treatment of schizophrenia patients in China. Amisulpride 103-114 cAMP responsive element modulator Homo sapiens 67-71 32597151-0 2020 Effect of amisulpride, olanzapine, quetiapine, and aripiprazole single administration on c-Fos expression in vasopressinergic and oxytocinergic neurons of the rat hypothalamic supraoptic nucleus. Amisulpride 10-21 Fos proto-oncogene, AP-1 transcription factor subunit Rattus norvegicus 89-94 32597151-8 2020 With respect to the stimulation efficacy of the individual antipsychotics, estimated based on the quantity of c-Fos-labeled AVP and OXY neurons, could be a preferential action assigned to QUE over moderate effect of ARI and lower effect to OLA and reduced effect of AMI (VEH < AMI < OLA < ARI < QUE). Amisulpride 266-269 Fos proto-oncogene, AP-1 transcription factor subunit Rattus norvegicus 110-115 32209227-5 2020 Characterisation of slit3 mutant larvae and adult fish revealed decreased sensitivity to the dopaminergic and serotonergic antagonist amisulpride, known to affect startle reflex that is correlated with addiction in humans, and increased htr1aa mRNA expression in mutant larvae. Amisulpride 134-145 slit homolog 3 (Drosophila) Danio rerio 20-25 32928616-6 2020 In a subsample of 185 patients (41.5%) with baseline PANSS P7 > 1, the PANSS P7 and PSP-D scores improved in the first 4 weeks of amisulpride treatment. Amisulpride 130-141 surfactant protein D Homo sapiens 84-89 32657631-7 2021 When patients were subdivided into those who were treated with risperidone, haloperidol, paliperidone, amisulpride, and a group that was not treated with these antipsychotics, aggressive patients in both groups had significantly higher PRL concentrations than non-aggressive patients. Amisulpride 103-114 prolactin Homo sapiens 236-239 31552612-6 2020 The effect of model-based average amisulpride concentrations over 24 h (Cav) on weight was estimated using a linear model. Amisulpride 34-45 caveolin 2 Homo sapiens 72-75 31842924-13 2019 CONCLUSIONS: Together our research indicates that the increased sensitivity of individuals with Alzheimer"s to amisulpride is related to previously unreported changes in function and expression of SLC transporters at the BBB (in particular PMAT and MATE1). Amisulpride 111-122 solute carrier family 47 member 1 Homo sapiens 249-254 31106995-7 2019 Results: Risperidone, paliperidone, and amisulpride are associated with higher prolactin levels than would be anticipated from striatal dopamine receptor occupancy studies. Amisulpride 40-51 prolactin Homo sapiens 79-88 31517634-0 2019 Spatial relationship between the c-Fos distribution and enkephalinergic, substance P, and tyrosine hydroxylase innervation fields after acute treatment with neuroleptics olanzapine, amisulpride, quetiapine, and aripiprazole in the rat septum. Amisulpride 182-193 Fos proto-oncogene, AP-1 transcription factor subunit Rattus norvegicus 33-38 31517634-1 2019 OBJECTIVE: The aim of the present study was to demonstrate the spatial relationship between the c-Fos immunoreactive cells elicited by an acute treatment with neuroleptics including amisulpride (AMI), olanzapine (OLA), quetiapine (QUE), and aripiprazole (ARI) and enkephalinergic (ENK), substance P (SP), and tyrosine hydroxylase (TH) innervation fields in the rat septum. Amisulpride 182-193 Fos proto-oncogene, AP-1 transcription factor subunit Rattus norvegicus 96-101 31517634-1 2019 OBJECTIVE: The aim of the present study was to demonstrate the spatial relationship between the c-Fos immunoreactive cells elicited by an acute treatment with neuroleptics including amisulpride (AMI), olanzapine (OLA), quetiapine (QUE), and aripiprazole (ARI) and enkephalinergic (ENK), substance P (SP), and tyrosine hydroxylase (TH) innervation fields in the rat septum. Amisulpride 195-198 Fos proto-oncogene, AP-1 transcription factor subunit Rattus norvegicus 96-101 30905743-0 2019 c-Fos expression response to olanzapine, amisulpride, aripiprazole, and quetiapine single administration in the rat forebrain: Effect of a mild stress preconditioning. Amisulpride 41-52 Fos proto-oncogene, AP-1 transcription factor subunit Rattus norvegicus 0-5 31106995-10 2019 Conclusions: The anatomy of the portal circulation, the presence of P-gp, and the high affinity of this protein to risperidone, paliperidone, and amisulpride all conspire to concentrate the antipsychotic concentration in the anterior pituitary to levels higher than in other parts of the brain, with consequent increase of prolactin above expectations. Amisulpride 146-157 prolactin Homo sapiens 323-332 29443543-3 2018 ABCB11199A recombinant cells had more sensitivity to olanzapine (2.2-fold, p < 0.01), aripiprazole (1.8-fold, p < 0.01), amisulpride (2.3-fold, p < 0.01), and risperidone (3.1-fold, p < 0.01) than ABCB1wt cells, while the resistance to paliperidone in both recombinant cell models was similar. Amisulpride 127-138 ATP binding cassette subfamily B member 1 Homo sapiens 0-5 30655509-5 2019 Compared to C1B, C2A and C2B patients, those from the C1A subtype exhibited the most severe symptoms and were the most at risk of being non-remitters when treated with the second-generation antipsychotic drug amisulpride. Amisulpride 209-220 secretoglobin family 2B member 3, pseudogene Homo sapiens 25-28 30655509-5 2019 Compared to C1B, C2A and C2B patients, those from the C1A subtype exhibited the most severe symptoms and were the most at risk of being non-remitters when treated with the second-generation antipsychotic drug amisulpride. Amisulpride 209-220 endogenous retrovirus group K member 1 Homo sapiens 54-57 29443543-4 2018 In addition, the uptake quality of olanzapine, aripiprazole, amisulpride, and risperidone in ABCB11199A recombinant cells was greatly decreased compared to ABCB1wt cells (3.2-fold, p < 0.01; 3.7-fold, p < 0.01; 3.1-fold, p < 0.01; 2.6-fold, and p < 0.01, respectively). Amisulpride 61-72 ATP binding cassette subfamily B member 1 Homo sapiens 93-98 29443543-5 2018 Furthermore, apparent permeability values were greatly increased in ABCB11199A recombinant cells compared with ABCB1wt recombinant cells for olanzapine (2.7-fold, p < 0.01), aripiprazole (2.9-fold, p < 0.01), amisulpride (3.4-fold, p < 0.01), and risperidone (4.1-fold, p < 0.01). Amisulpride 215-226 ATP binding cassette subfamily B member 1 Homo sapiens 68-73 30506237-10 2019 Prolactin elevation is highest with paliperidone, risperidone, and amisulpride. Amisulpride 67-78 prolactin Homo sapiens 0-9 30144664-3 2018 METHODS: The present study examines the differential effects of time-dependent treatment with haloperidol, olanzapine and amisulpride (20muM) on VEGF and MAPK mRNA expression and VEGF level, using the T98 cell line as an example of nerve cells. Amisulpride 122-133 vascular endothelial growth factor A Homo sapiens 145-149 30144664-3 2018 METHODS: The present study examines the differential effects of time-dependent treatment with haloperidol, olanzapine and amisulpride (20muM) on VEGF and MAPK mRNA expression and VEGF level, using the T98 cell line as an example of nerve cells. Amisulpride 122-133 vascular endothelial growth factor A Homo sapiens 179-183 27900577-5 2017 Real-time polymerase chain reaction (PCR) was used to examine the effects of haloperidol, olanzapine and amisulpride on the expression of genes coding PAC1/VPAC type receptors in the T98G glioblastoma cell line, as an example of an in vitro model of glial cells. Amisulpride 105-116 ADCYAP receptor type I Homo sapiens 151-155 28947383-0 2017 Polymorphism of the SNAP25 gene is associated with symptom improvement in schizophrenic patients treated with amisulpride. Amisulpride 110-121 synaptosome associated protein 25 Homo sapiens 20-26 28947383-2 2017 Thus, the present study investigated the associations between polymorphisms of SNAP25 and the treatment response to amisulpride in patients with schizophrenia. Amisulpride 116-127 synaptosome associated protein 25 Homo sapiens 79-85 29477044-4 2018 METHODS: The direct effect of haloperidol, clozapine, olanzapine, quetiapine and amisulpride on p110delta enzymatic activity was tested with a kinase assay, and the results were referenced against data on the mRNA expression of PIK3CD. Amisulpride 81-92 phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta Homo sapiens 96-105 29477044-5 2018 RESULTS: Haloperidol, clozapine, olanzapine and quetiapine, but not amisulpride, at the concentration of 20-80 muM, were found to significantly increase enzymatic activity of p110delta by up to two times in a dose-dependent manner. Amisulpride 68-79 phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta Homo sapiens 175-184 29182611-3 2017 The present study examines the effects of a first-generation neuroleptic drug (FGA; haloperidol) and two second-generation neuroleptic drugs (SGAs; olanzapine and amisulpride) on the expression and levels of brain-derived neurotrophic factor (BDNF) in an astrocyte-like T98G glioblastoma cell line. Amisulpride 163-174 brain derived neurotrophic factor Homo sapiens 208-241 28332719-0 2017 rs7968606 polymorphism of ANKS1B is associated with improvement in the PANSS general score of schizophrenia caused by amisulpride. Amisulpride 118-129 ankyrin repeat and sterile alpha motif domain containing 1B Homo sapiens 26-32 28332719-2 2017 The aim of this study was to determine the association between the rs7968606 SNP of ANKS1B and the treatment response to amisulpride in schizophrenia patients. Amisulpride 121-132 ankyrin repeat and sterile alpha motif domain containing 1B Homo sapiens 84-90 28332719-7 2017 To the best of our knowledge, this is the first genetic association study of the relationship between the rs7968606 SNP of ANKS1B and the response of schizophrenia patients to treatment with amisulpride. Amisulpride 191-202 ankyrin repeat and sterile alpha motif domain containing 1B Homo sapiens 123-129 28332719-8 2017 Future larger-scale studies involving more SNPs of ANKS1B will improve the understanding of the pharmacogenetics underlying the treatment responses to amisulpride. Amisulpride 151-162 ankyrin repeat and sterile alpha motif domain containing 1B Homo sapiens 51-57 27903552-5 2017 Additionally, six impurities of amisulpride were identified by the use of MS/MS fragmentation and one of them was found as the main impurity (Imp-1) and can be regarded as the primary impurity "marker" for the analyzed formulations. Amisulpride 32-43 insulin like growth factor 2 mRNA binding protein 1 Homo sapiens 142-147 29182611-3 2017 The present study examines the effects of a first-generation neuroleptic drug (FGA; haloperidol) and two second-generation neuroleptic drugs (SGAs; olanzapine and amisulpride) on the expression and levels of brain-derived neurotrophic factor (BDNF) in an astrocyte-like T98G glioblastoma cell line. Amisulpride 163-174 brain derived neurotrophic factor Homo sapiens 243-247 26754356-6 2016 Good orthogonality (>0.9) separation was achieved and three AChE inhibitors (tiapride, amisulpride, and lamotrigine), used as antipsychotic medicines, were identified and confirmed by two-dimensional retention alignment as well as their AChE inhibition activity. Amisulpride 90-101 acetylcholinesterase (Cartwright blood group) Homo sapiens 63-67 26724569-0 2016 Catechol-O-methyltransferase gene variants may associate with negative symptom response and plasma concentrations of prolactin in schizophrenia after amisulpride treatment. Amisulpride 150-161 catechol-O-methyltransferase Homo sapiens 0-28 26724569-0 2016 Catechol-O-methyltransferase gene variants may associate with negative symptom response and plasma concentrations of prolactin in schizophrenia after amisulpride treatment. Amisulpride 150-161 prolactin Homo sapiens 117-126 26724569-2 2016 The aim of this study was to examine the relationship between COMT variants, plasma prolactin level, and the therapeutic effectiveness of amisulpride treatment in patients with schizophrenia. Amisulpride 138-149 catechol-O-methyltransferase Homo sapiens 62-66 26724569-2 2016 The aim of this study was to examine the relationship between COMT variants, plasma prolactin level, and the therapeutic effectiveness of amisulpride treatment in patients with schizophrenia. Amisulpride 138-149 prolactin Homo sapiens 84-93 26724569-11 2016 Our results suggest that variation of the COMT gene is associated with treatment response regarding negative symptoms and prolactin changes after amisulpride treatment in patients with schizophrenia. Amisulpride 146-157 catechol-O-methyltransferase Homo sapiens 42-46 26724569-11 2016 Our results suggest that variation of the COMT gene is associated with treatment response regarding negative symptoms and prolactin changes after amisulpride treatment in patients with schizophrenia. Amisulpride 146-157 prolactin Homo sapiens 122-131 26453696-8 2015 Although the treatment with amisulpride significantly improved the patients" psychopathological (PANSS) and functional (GAF) scores, it did not influence their mismatch negativity amplitude, while also their reduced P3a amplitude persisted. Amisulpride 28-39 fibroblast growth factor 9 Homo sapiens 120-123 25679126-1 2015 The aim of this study was to identify the association between the rs1079597 and rs1800497 genetic polymorphisms of the gene encoding the dopamine D2 receptor (DRD2) protein and the treatment response to the selective dopamine receptor antagonist amisulpride. Amisulpride 246-257 dopamine receptor D2 Homo sapiens 137-157 26270200-6 2015 In addition, an obvious increase in PRL level and a reduction of sex hormone secretion after amisulpride treatment were found. Amisulpride 93-104 prolactin Homo sapiens 36-39 26270200-9 2015 CONCLUSIONS: The PRL-raising antipsychotic drug amisulpride influenced bone turnover balance very early in the course of treatment, which may require long-term monitoring of bone metabolism. Amisulpride 48-59 prolactin Homo sapiens 17-20 25679126-0 2015 DRD2 genotypic and haplotype variation is associated with improvements in negative symptoms after 6 weeks" amisulpride treatment. Amisulpride 107-118 dopamine receptor D2 Homo sapiens 0-4 25679126-1 2015 The aim of this study was to identify the association between the rs1079597 and rs1800497 genetic polymorphisms of the gene encoding the dopamine D2 receptor (DRD2) protein and the treatment response to the selective dopamine receptor antagonist amisulpride. Amisulpride 246-257 dopamine receptor D2 Homo sapiens 159-163 25679126-8 2015 A larger scale study involving more single nucleotide polymorphisms of DRD2 will progress the research into the pharmacogenetics of the treatment response to amisulpride. Amisulpride 158-169 dopamine receptor D2 Homo sapiens 71-75 24954063-2 2014 In the present study, the effects of a potent D2/D3 receptor antagonist, amisulpride, were investigated on PPI and P50 gating in a large sample of antipsychotic-naive, first-episode patients with schizophrenia. Amisulpride 73-84 activating signal cointegrator 1 complex subunit 1 Homo sapiens 115-118 24619919-1 2015 Amisulpride, a selective antagonist of D2 and D3 dopamine receptors, is used as an antipsychotic drug. Amisulpride 0-11 dopamine receptor D2 Rattus norvegicus 39-67 24801767-7 2014 Clinically associated symptoms were evaluated using the SCL-90-R. Aripiprazole, risperidone, and amisulpride increased P50 suppression in low P50 gaters. Amisulpride 97-108 nuclear factor kappa B subunit 1 Homo sapiens 119-122 25155823-5 2014 We then studied the uptake of amisulpride and sulpiride by the organic cation transporters of the SLC22 family OCT1, OCT2, OCT3, OCTN1, and OCTN2 Amisulpride was found to be transported by all five transporters studied. Amisulpride 30-41 solute carrier family 22 member 2 Homo sapiens 117-121 25155823-5 2014 We then studied the uptake of amisulpride and sulpiride by the organic cation transporters of the SLC22 family OCT1, OCT2, OCT3, OCTN1, and OCTN2 Amisulpride was found to be transported by all five transporters studied. Amisulpride 30-41 solute carrier family 22 member 3 Homo sapiens 123-127 25155823-5 2014 We then studied the uptake of amisulpride and sulpiride by the organic cation transporters of the SLC22 family OCT1, OCT2, OCT3, OCTN1, and OCTN2 Amisulpride was found to be transported by all five transporters studied. Amisulpride 30-41 solute carrier family 22 member 4 Homo sapiens 129-134 25155823-5 2014 We then studied the uptake of amisulpride and sulpiride by the organic cation transporters of the SLC22 family OCT1, OCT2, OCT3, OCTN1, and OCTN2 Amisulpride was found to be transported by all five transporters studied. Amisulpride 30-41 solute carrier family 22 member 5 Homo sapiens 140-145 25155823-5 2014 We then studied the uptake of amisulpride and sulpiride by the organic cation transporters of the SLC22 family OCT1, OCT2, OCT3, OCTN1, and OCTN2 Amisulpride was found to be transported by all five transporters studied. Amisulpride 146-157 solute carrier family 22 member 1 Homo sapiens 111-115 25155823-5 2014 We then studied the uptake of amisulpride and sulpiride by the organic cation transporters of the SLC22 family OCT1, OCT2, OCT3, OCTN1, and OCTN2 Amisulpride was found to be transported by all five transporters studied. Amisulpride 146-157 solute carrier family 22 member 2 Homo sapiens 117-121 25155823-5 2014 We then studied the uptake of amisulpride and sulpiride by the organic cation transporters of the SLC22 family OCT1, OCT2, OCT3, OCTN1, and OCTN2 Amisulpride was found to be transported by all five transporters studied. Amisulpride 146-157 solute carrier family 22 member 4 Homo sapiens 129-134 25155823-5 2014 We then studied the uptake of amisulpride and sulpiride by the organic cation transporters of the SLC22 family OCT1, OCT2, OCT3, OCTN1, and OCTN2 Amisulpride was found to be transported by all five transporters studied. Amisulpride 146-157 solute carrier family 22 member 5 Homo sapiens 140-145 25155823-7 2014 OCT1 showed the highest transport ability both for amisulpride (CLint = 1.9 ml/min/mg protein) and sulpiride (CLint = 4.2 ml/min/mg protein) and polymorphisms in OCT1 significantly reduced the uptake of both drugs. Amisulpride 51-62 solute carrier family 22 member 1 Homo sapiens 0-4 24801767-7 2014 Clinically associated symptoms were evaluated using the SCL-90-R. Aripiprazole, risperidone, and amisulpride increased P50 suppression in low P50 gaters. Amisulpride 97-108 nuclear factor kappa B subunit 1 Homo sapiens 142-145 24794879-9 2014 Percent SANS improvement at endpoint was greatest for the rapid-responders group, a finding that replicated stratifying by placebo and amisulpride treatment groups. Amisulpride 135-146 USH1 protein network component sans Homo sapiens 8-12 23470610-10 2013 RESULTS: Twenty patients received amisulpride with ECT. Amisulpride 34-45 ECT Homo sapiens 51-54 24847420-4 2014 Therefore, we aimed to investigate the effects of fluphenazine and amisulpride on brain regional contents of neurotensin considering the role of cannabinoid CB1 receptors which interact with neurotensin neurotransmission. Amisulpride 67-78 neurotensin Rattus norvegicus 109-120 24847420-8 2014 RESULTS: Chronic, but not acute, treatment with the highest dose of fluphenazine or amisulpride resulted in significant enhancement of neurotensin contents in the prefronatal cortex and nucleus accumbens. Amisulpride 84-95 neurotensin Rattus norvegicus 135-146 24847420-13 2014 CONCLUSION: The brain neurotensin under the regulatory action of CB1 receptors is involved in the effects of amisulpride and fluphenazine. Amisulpride 110-121 neurotensin Rattus norvegicus 22-33 24847420-13 2014 CONCLUSION: The brain neurotensin under the regulatory action of CB1 receptors is involved in the effects of amisulpride and fluphenazine. Amisulpride 110-121 cannabinoid receptor 1 Rattus norvegicus 65-68 23643745-6 2013 Amisulpride also attenuated the hypolocomotion induced by the D2/D3 receptor agonist pramipexole and dopamine precursor l-3,4-dihydroxyphenylalanine, whereas raclopride (and S33084) worsened it. Amisulpride 0-11 dopamine receptor D2 Mus musculus 62-76 24677189-8 2014 Although the highest rates of HPRL are consistently reported in association with amisulpride, risperidone and paliperidone, while aripiprazole and quetiapine have the most favorable profile with respect to this outcome, all SGAs can induce PRL elevations, especially at the beginning of treatment, and have the potential to cause new-onset HPRL. Amisulpride 81-92 prolactin Homo sapiens 31-34 24677189-11 2014 However, antipsychotics having a high potential for PRL elevation (amisulpride, risperidone and paliperidone) can have a profound impact on PRL levels even at relatively low doses, while PRL levels with antipsychotics having a minimal effect on PRL, in most cases, can remain unchanged (quetiapine) or reduce (aripiprazole) over all dosages. Amisulpride 67-78 prolactin Homo sapiens 52-55 24677189-11 2014 However, antipsychotics having a high potential for PRL elevation (amisulpride, risperidone and paliperidone) can have a profound impact on PRL levels even at relatively low doses, while PRL levels with antipsychotics having a minimal effect on PRL, in most cases, can remain unchanged (quetiapine) or reduce (aripiprazole) over all dosages. Amisulpride 67-78 prolactin Homo sapiens 140-143 24677189-11 2014 However, antipsychotics having a high potential for PRL elevation (amisulpride, risperidone and paliperidone) can have a profound impact on PRL levels even at relatively low doses, while PRL levels with antipsychotics having a minimal effect on PRL, in most cases, can remain unchanged (quetiapine) or reduce (aripiprazole) over all dosages. Amisulpride 67-78 prolactin Homo sapiens 140-143 24677189-11 2014 However, antipsychotics having a high potential for PRL elevation (amisulpride, risperidone and paliperidone) can have a profound impact on PRL levels even at relatively low doses, while PRL levels with antipsychotics having a minimal effect on PRL, in most cases, can remain unchanged (quetiapine) or reduce (aripiprazole) over all dosages. Amisulpride 67-78 prolactin Homo sapiens 140-143 25535442-8 2014 RESULTS: The mean SANS score in amisulpride and olanzapine group at day 0 and day 60 were 83.89 (+-12.67) and 21.00 (+-11.82) and 84.40 (+-13.22) and 26.75 (+-12.41), respectively. Amisulpride 32-43 USH1 protein network component sans Homo sapiens 18-22 25535442-10 2014 The percentage improvement in SANS, SAPS, SCoRS interviewer, and SCoRS global in amisulpride group are 74.96%, 13.36%, 54.14%, and 42.00%, respectively. Amisulpride 81-92 USH1 protein network component sans Homo sapiens 30-34 23218563-7 2013 Kaplan-Meier and Cox survival models to adjust for baseline symptom severity showed that compared with the placebo group the amisulpride group attained significantly (p<.05) more remission sooner (HR=2.321, 95% CI=1.36, to 3.97, p<.05). Amisulpride 125-136 cytochrome c oxidase subunit 8A Homo sapiens 17-20 22426845-3 2012 PATIENTS AND METHODS: In this study we compared the acute, non-adiposity related effects of a single dose of olanzapine, amisulpride and placebo on insulin sensitivity and secretion in 10 healthy subjects in a randomised, double blind cross-over design. Amisulpride 121-132 insulin Homo sapiens 148-155 22999925-0 2012 Choline acetyltransferase expression in rat prefrontal cortex and hippocampus after acute and chronic exposure to amisulpride, haloperidol, and risperidone. Amisulpride 114-125 choline O-acetyltransferase Rattus norvegicus 0-25 22525746-8 2012 and assessing brain and serum levels by HPLC analysis, P-gp expression has the highest but a rather short effect on the distribution of amisulpride, whereas the others ranked N-desmethylclozapine>olanzapine>quetiapine>clozapine; contrasted by in vivo behavioral changes at various time points. Amisulpride 136-147 phosphoglycolate phosphatase Mus musculus 55-59 23983946-10 2011 CONCLUSIONS: The clinical data from the present study supports the fact that amisulpride is an effective and safe antipsychotic drug, but elevates prolactin levels in both sexes. Amisulpride 77-88 prolactin Homo sapiens 147-156 22411694-0 2012 Relationship between prolactin levels and subjective endocrine-related adverse effects in patients with schizophrenia receiving long-term treatment with amisulpride. Amisulpride 153-164 prolactin Homo sapiens 21-30 22309430-2 2012 CASE PRESENTATION: We report the case of a 50-year-old Caucasian female patient with schizophrenia and cytochrome P450 2D6 ultrarapid metabolizer status who experienced an insufficient antipsychotic effect with amisulpride. Amisulpride 211-222 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 103-122 23530420-2 2012 A decrease in activity of humoral immunity factors (B lymphocytes, immunoglobulins, HLADR(+)-cells) identified among schizophrenic patients in the process of amisulpride therapy can be attributed to a positive effect optimizing the ratio Th1/Th2. Amisulpride 158-169 negative elongation factor complex member C/D Homo sapiens 238-241 22472310-2 2012 Higher levels of prolactin result from longer exposure to higher doses, especially with older antipsychotics or with risperidone, sulpiride or amisulpride. Amisulpride 143-154 prolactin Homo sapiens 17-26 22250612-3 2012 The aim of this study was to examine whether low dosages of amisulpride can increase serum levels of prolactin or not clinically in Korean patients. Amisulpride 60-71 prolactin Homo sapiens 101-110 22250612-4 2012 METHOD: Serum prolactin levels were measured in 20 Korean patients (12 men and eight women) with various diagnoses who were treated with less than 300 mg of amisulpride per day. Amisulpride 157-168 prolactin Homo sapiens 14-23 22250612-7 2012 CONCLUSIONS: The low dosages of amisulpride elevate serum prolactin level in the majority of patients. Amisulpride 32-43 prolactin Homo sapiens 58-67 22250612-9 2012 Clinicians should monitor serum prolactin level even when low dosages of amisulpride are administered. Amisulpride 73-84 prolactin Homo sapiens 32-41 21663752-0 2011 Differential effects of amisulpride and haloperidol on dopamine D2 receptor-mediated signaling in SH-SY5Y cells. Amisulpride 24-35 dopamine receptor D2 Homo sapiens 55-75 22713195-3 2011 Conventional antipsychotics and some of the atypical antipsychotics, such as risperidone, paliperidone, amisulpride and zotepine, are frequently associated with the raise in prolactin plasma levels. Amisulpride 104-115 prolactin Homo sapiens 174-183 21663752-3 2011 In the present study, we compared the effects of amisulpride and haloperidol on the beta-arrestin 2-mediated Akt/GSK-3beta pathway in SH-SY5Y cells. Amisulpride 49-60 arrestin beta 2 Homo sapiens 84-99 21663752-3 2011 In the present study, we compared the effects of amisulpride and haloperidol on the beta-arrestin 2-mediated Akt/GSK-3beta pathway in SH-SY5Y cells. Amisulpride 49-60 AKT serine/threonine kinase 1 Homo sapiens 109-112 21663752-3 2011 In the present study, we compared the effects of amisulpride and haloperidol on the beta-arrestin 2-mediated Akt/GSK-3beta pathway in SH-SY5Y cells. Amisulpride 49-60 glycogen synthase kinase 3 beta Homo sapiens 113-122 21663752-7 2011 Small interfering RNA (siRNA) for beta-arrestin 2 knockdown blocked the increase in amisulpride-induced neurite outgrowth. Amisulpride 84-95 arrestin beta 2 Homo sapiens 34-49 21663752-8 2011 Furthermore, amisulpride increased the levels of Akt and GSK-3beta phosphorylation, while haloperidol had no effect. Amisulpride 13-24 AKT serine/threonine kinase 1 Homo sapiens 49-52 21663752-8 2011 Furthermore, amisulpride increased the levels of Akt and GSK-3beta phosphorylation, while haloperidol had no effect. Amisulpride 13-24 glycogen synthase kinase 3 beta Homo sapiens 57-66 21663752-9 2011 The elevation of Akt phosphorylation induced by amisulpride was reduced by beta-arrestin 2 siRNA. Amisulpride 48-59 AKT serine/threonine kinase 1 Homo sapiens 17-20 21663752-9 2011 The elevation of Akt phosphorylation induced by amisulpride was reduced by beta-arrestin 2 siRNA. Amisulpride 48-59 arrestin beta 2 Homo sapiens 75-90 21663752-10 2011 Moreover, amisulpride effectively increased the levels of phospho-CREB, BDNF, and Bcl-2. Amisulpride 10-21 cAMP responsive element binding protein 1 Homo sapiens 66-70 21663752-10 2011 Moreover, amisulpride effectively increased the levels of phospho-CREB, BDNF, and Bcl-2. Amisulpride 10-21 brain derived neurotrophic factor Homo sapiens 72-76 21663752-10 2011 Moreover, amisulpride effectively increased the levels of phospho-CREB, BDNF, and Bcl-2. Amisulpride 10-21 BCL2 apoptosis regulator Homo sapiens 82-87 21663752-12 2011 Additionally, wortmannin, a phosphatidylinositol 3-kinase (PI3 K) inhibitor, blocked the stimulatory effect of amisulpride on phosphorylated Akt. Amisulpride 111-122 AKT serine/threonine kinase 1 Homo sapiens 141-144 21663752-13 2011 Together, these results suggest that regulation of the beta-arrestin 2-dependent pathway via blockade of the D(2)R in SH-SY5Y cells is one mechanism underlying the neuroprotective effect of amisulpride, but not haloperidol. Amisulpride 190-201 arrestin beta 2 Homo sapiens 55-70 21385106-5 2011 EXPERT OPINION: Typical antipsychotics, in addition to the atypical antipsychotics risperidone and amisulpride, have been shown to increase serum prolactin levels in in vivo human studies. Amisulpride 99-110 prolactin Homo sapiens 146-155 21670104-5 2011 Using a bioluminescence resonance energy transfer biosensor for cAMP, we demonstrated that the D2R antagonists haloperidol, raclopride, and amisulpride were able to enhance selectively a TAAR1-mediated beta-PEA increase of cAMP. Amisulpride 140-151 dopamine receptor D2 Homo sapiens 95-98 21670104-5 2011 Using a bioluminescence resonance energy transfer biosensor for cAMP, we demonstrated that the D2R antagonists haloperidol, raclopride, and amisulpride were able to enhance selectively a TAAR1-mediated beta-PEA increase of cAMP. Amisulpride 140-151 trace amine associated receptor 1 Homo sapiens 187-192 20218789-3 2010 We measured serum BDNF levels in 47 patients with schizophrenia during a relapse and again 6 weeks after administration of antipsychotic treatment (14 on risperidone, 18 on haloperidol, 10 on olanzapine and five on amisulpride) and in 44 healthy volunteers. Amisulpride 215-226 brain derived neurotrophic factor Homo sapiens 18-22 21289169-3 2011 We combined administration of the dopamine D(2) receptor antagonist amisulpride with functional magnetic resonance imaging in healthy human volunteers. Amisulpride 68-79 dopamine receptor D2 Homo sapiens 34-56 19910716-8 2009 During the treatment course, the amisulpride-treated patients showed significantly decreased fasting triglyceride, total cholesterol, glucose, and insulin resistance levels; decreased diastolic blood pressure and pulse rate; and a significant increase in high-density lipoprotein cholesterol levels after switching to amisulpride (all with a P < 0.05). Amisulpride 33-44 insulin Homo sapiens 147-154